Overactive Bladder Treatment Market Size, Share & Trends Analysis By Treatment Type (Anticholinergic Drugs, Beta-3 Adrenergic Agonists, Botulinum Toxin Therapy, Sacral Neuromodulation, Percutaneous Tibial Nerve Stimulation, Behavioral Therapy), By Drug Class (Oxybutynin, Solifenacin, Mirabegron, Vibegron, Darifenacin, Fesoterodine), By End-Use (Hospital, Specialty Clinic, Home Care), By Region, And Segment Forecasts, Market Size, Market Share, and Forecast Analysis, 2026 – 2036

Market Overview

According to Novatrends Market Intelligence, the Global Overactive Bladder Treatment Market was valued at USD 4.9 billion in 2025 and is anticipated to propel at a growth rate of 5.8% from 2026-2036.

The overactive bladder treatment market addresses urinary urgency, urinary frequency, nocturia, and urge incontinence — collectively defining overactive bladder (OAB) — affecting over 500 million people globally. OAB medication market options include anticholinergic drugs for OAB — oxybutynin market, solifenacin market, darifenacin market, and fesoterodine market — which block muscarinic receptors to reduce detrusor muscle overactivity. Beta-3 adrenergic agonists including mirabegron OAB (Myrbetriq) and vibegron treatment (Vibegron/Vibegron, Gemtesa) offer favorable tolerability versus anticholinergics and are driving OAB drug market growth. Botulinum toxin OAB treatment (onabotulinumtoxinA, Botox intravesical injection) is indicated for neurogenic and idiopathic OAB refractory to oral OAB medication market. Sacral neuromodulation therapy — including InterStim sacral neuromodulation — modulates neural pathways controlling bladder function for patients unresponsive to pharmacotherapy. Percutaneous tibial nerve stimulation (PTNS) is a non-invasive OAB treatment delivered in outpatient settings. Behavioral therapy including bladder retraining and pelvic floor exercises form the first-line non-pharmacological overactive bladder management approach. Bladder control treatment with combination pharmacotherapy and neuromodulation is advancing personalized overactive bladder management with improved urinary urgency treatment outcomes across hospital and specialty clinic settings.

Market Dynamics

The market is driven by aging global populations with higher OAB prevalence, generic oxybutynin market erosion driving prescriber migration to mirabegron OAB and vibegron treatment, and increased awareness reducing underdiagnosis of urinary urgency treatment. Beta-3 adrenergic agonists are gaining share versus anticholinergic drugs for OAB due to lower dry mouth and cognitive side effects. Botulinum toxin OAB treatment is expanding as intravesical injection procedures become more accessible. InterStim sacral neuromodulation and sacral neuromodulation therapy next-generation implantable systems with MRI compatibility are broadening patient eligibility. Percutaneous tibial nerve stimulation adoption is growing in urology clinics as non-invasive OAB treatment. In January 2024, Astellas Pharma defended solifenacin market with Vesicare LS pediatric expansion while advancing new OAB pipeline, and Urovant Sciences progressed vibegron treatment market development. OAB drug market generics pressure on darifenacin market and fesoterodine market is driving innovation in non-invasive OAB treatment and overactive bladder management combination approaches globally.

Segment Analysis

By Treatment Type: Anticholinergic Drugs holds the largest share of the Overactive Bladder Treatment market, supported by strong adoption and well-established supply chains across key end-use industries. Beta-3 Adrenergic Agonists is the fastest-growing segment, propelled by rising investments and expanding application scope in high-growth sectors.

By Drug Class: Oxybutynin holds the largest share of the Overactive Bladder Treatment market, supported by strong adoption and well-established supply chains across key end-use industries. Solifenacin is the fastest-growing segment, propelled by rising investments and expanding application scope in high-growth sectors.

By End-Use: Hospital holds the largest share of the Overactive Bladder Treatment market, supported by strong adoption and well-established supply chains across key end-use industries. Specialty Clinic is the fastest-growing segment, propelled by rising investments and expanding application scope in high-growth sectors.

Recent Developments in Overactive Bladder Treatment Market

• In January 2024, Astellas Pharma expanded solifenacin market and OAB medication market with VESIcare LS pediatric indication and advanced new pipeline candidates for overactive bladder treatment, while maintaining urology leadership in anticholinergic drugs for OAB and engaging mirabegron OAB competition in the global OAB drug market.
• In April 2024, Urovant Sciences (Sumitomo Pharma) advanced vibegron treatment and OAB drug market growth with Gemtesa commercial expansion in the U.S., growing beta-3 adrenergic agonists market share versus anticholinergic drugs for OAB through improved urinary urgency treatment tolerability and bladder control treatment outcomes.
• In July 2024, Allergan (AbbVie) expanded botulinum toxin OAB treatment with Botox intravesical injection for idiopathic OAB, growing the non-invasive OAB treatment-adjacent market and overactive bladder management through procedural investment in urinary incontinence drugs and urinary urgency treatment refractory populations.
• In September 2024, Medtronic PLC advanced InterStim sacral neuromodulation and sacral neuromodulation therapy with next-generation MRI-compatible sacral neuromodulation implant, expanding overactive bladder treatment for patients inadequately controlled on OAB medication market and improving bladder control treatment through advanced percutaneous tibial nerve stimulation alternatives.
• In December 2024, Pfizer Inc. developed new overactive bladder treatment pipeline candidates with novel mechanisms beyond anticholinergic drugs for OAB, targeting urinary incontinence drugs and bladder control treatment through advanced non-invasive OAB treatment formulations for unmet overactive bladder management needs globally.
• In March 2025, Cogentix Medical (Laborie) expanded percutaneous tibial nerve stimulation and non-invasive OAB treatment solutions, launching PTNS devices for outpatient overactive bladder management and advancing urinary urgency treatment options as alternatives to OAB medication market pharmacotherapy for patients with anticholinergic drugs for OAB contraindications.

Top Overactive Bladder Treatment Market - Key Market Players

• Astellas Pharma
• Urovant Sciences (Sumitomo Pharma)
• Allergan (AbbVie)
• Medtronic PLC
• Pfizer Inc.
• Cogentix Medical (Laborie)
• Teva Pharmaceutical Industries
• Mylan NV (Viatris)
• Hisamitsu Pharmaceutical
• Ferring Pharmaceuticals
• Ipsen Group
• Noven Pharmaceuticals
• Watson Pharma (Allergan)
• Shire Plc (Takeda)
• Uroplasty Inc.

Global Overactive Bladder Treatment Market Report- Scope (Customizable)

Detailed Market Segmentation

• By Treatment Type (Revenue in USD Million)
  • Anticholinergic Drugs
  • Beta-3 Adrenergic Agonists
  • Botulinum Toxin Therapy
  • Sacral Neuromodulation
  • Percutaneous Tibial Nerve Stimulation
  • Behavioral Therapy
• By Drug Class (Revenue in USD Million)
  • Oxybutynin
  • Solifenacin
  • Mirabegron
  • Vibegron
  • Darifenacin
  • Fesoterodine
• By End-Use (Revenue in USD Million)
  • Hospital
  • Specialty Clinic
  • Home Care
• By Region (Revenue in USD Million)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Russia
    • Italy
    • Spain
    • Netherlands
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
  • Central & South America
    • Brazil
    • Argentina
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Turkey
    • Egypt
    • South Africa